Peptyde Bio’s 2023 acquisition by Invaio Sciences highlights the strength of St. Louis’ agtech ecosystem and the value of early-stage support. As an early investor, BioGenerator supported Peptyde Bio’s growth, helping advance its path from breakthrough research at the Donald Danforth Plant Science Center to successful commercialization and acquisition. The deal not only validated the company’s peptide-based technology, but also created ongoing collaboration, retained talent locally, and increased national visibility for the region’s innovation pipeline.
